Wang Jianzhong, Xue Jiao, Kong Jingyuan, Li Jing, Zhang Suxia, Cao Xingyuan
Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Laboratory of Quality & Safety Risk Assessment for Animal Products on Chemical Hazards (Beijing), Ministry of Agriculture and Rural affairs, Beijing, China.
J Vet Pharmacol Ther. 2018 Dec;41(6):843-847. doi: 10.1111/jvp.12703. Epub 2018 Aug 3.
The pharmacokinetic properties of vitacoxib have not been established completely; current dosage recommendations are based on clinical experiences. The primary objective of this study was to describe plasma concentrations and characterize the pharmacokinetics of vitacoxib formulation following oral administrations in horses. Also, the effect of the state of stomach contents on the absorption of vitacoxib was investigated in fed/fasted horses. Blood samples were collected prior to and at various times up to 72 hr post-administration. Drug concentrations were measured using ultra high-performance liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters were calculated using Non-Compartmental Analysis Model 200 in WinNonlin™ software. No complications resulting from the vitacoxib administration were noted. All procedures were tolerated well by the horses throughout the study. C was 17.5 ± 9.36 ng/ml (fasted) and 9.47 ± 3.53 ng/ml (fed) following oral administrations. AUC was 173.7 ± 137.9 ng hr/ml (fasted) and 113.2 ± 70.8 ng h/ml (fed). No significant differences in pharmacokinetic parameters were noted and the results from the pharmacokinetic analysis were similar between the studies, regardless of precision of dosage and fasted and fed conditions. The study extends previous studies describing the pharmacokinetics of vitacoxib following p.o. administration to the horses. Further studies investigating the pharmacokinetics/pharmacodynamics of vitacoxib are necessary to establish adequate therapeutic protocols (optimal dosage and frequency of administration) in horses.
维他考昔的药代动力学特性尚未完全明确;目前的剂量建议是基于临床经验。本研究的主要目的是描述马匹口服维他考昔制剂后的血浆浓度并表征其药代动力学特征。此外,还研究了饱腹/空腹状态下胃内容物状态对维他考昔吸收的影响。在给药前及给药后长达72小时的不同时间点采集血样。使用超高效液相色谱-串联质谱法测量药物浓度。使用WinNonlin™软件中的非房室分析模型200计算药代动力学参数。未观察到维他考昔给药引起的并发症。在整个研究过程中,马匹对所有操作耐受良好。口服给药后,空腹时的C为17.5±9.36 ng/ml,饱腹时为9.47±3.53 ng/ml。AUC空腹时为173.7±137.9 ng·hr/ml,饱腹时为113.2±70.8 ng·h/ml。药代动力学参数未观察到显著差异,且无论给药剂量的精确性以及空腹和饱腹状态如何,药代动力学分析结果在各研究之间相似。本研究扩展了先前关于马匹口服维他考昔药代动力学的研究。有必要进一步开展研究以探究维他考昔的药代动力学/药效学,从而制定出适用于马匹的充分治疗方案(最佳剂量和给药频率)。